Skip to main content

Table 1 Immunotherapies targeting Aβ in AD drug development

From: Immunotherapy for Alzheimer’s disease: targeting β-amyloid and beyond

Therapeutic strategy

Drug

Mechanism

Sponsor

Study population

Admin

Phase

Results

Clinical Trial Identifier

Start date

Estimated end date

Active immunotherapy

AN1792

Vaccination

Janssen/Pfizer

Mild to moderate AD

IM

II

Terminated

NCT00021723

2001 Sept

2003 Sept

Amilomotide

(CAD106)

Vaccination

Novartis

Participants at risk of the onset of clinical symptoms of AD

IM

II/III

Terminated

NCT02565511

2015 Nov

2020 Apr

UB-311

Vaccination

United Neuro-science

Mild AD

IM

II

Completed

NCT02551809

2015 Oct

2018 Aug

   

Mild AD

 

II

Terminated

NCT03531710

2018 Aug

2019 Oct

ABvac40

Vaccination

Araclon Biotech

Participants with amnestic mild cognitive impairment or very mild AD

SC

II

Active, not recruiting

NCT03461276

2018 Feb

2022 Dec

Passive immunotherapy

Solanezumab

(LY2062430)

Monoclonal antibody

Eli Lilly

Mild to moderate AD

IV

III

Completed

NCT00905372

2009 May

2012 Apr

   

Mild to moderate AD

  

Completed

NCT00904683

2009 May

2012 Jun

   

Mild to moderate AD

  

Terminated

NCT01127633

2010 Dec

2017 Feb

   

Mild AD

 

III

Terminated

NCT01900665

2013 Jul

2016 Oct

   

Prodromal AD

 

III

Terminated

NCT02760602

2016 Jun

2017 May

   

Participants at risk of memory loss

 

III

Active, not recruiting

NCT02008357

2014 Feb

2022 Dec

Gantenerumab

Monoclonal antibody

Roche

Prodromal AD

IV

 

Completed

NCT01224106

2010 Nov

2020 Sept

   

Mild AD

  

Completed

NCT02051608

2014 Mar

2021 Apr

   

Prodromal to mild AD

  

Recruiting

NCT04374253

2014 Mar

2021 Apr

   

Early AD

  

Recruiting

NCT03444870

2018 Jun

2023 Nov

   

Early AD

  

Active, not recruiting

NCT03443973

2018 Aug

2022 Sept

   

Early AD

  

Active, not recruiting

NCT04339413

2020 May

2023 Apr

Aducanumab

(BIIB037)

Monoclonal antibody

Biogen

Early AD

IV

III

Terminated

NCT02484547

2015 Sept

2019 Aug

   

Early AD

 

III

Terminated

NCT02477800

2015 Aug

2019 Aug

   

Early AD

 

III

Active, not recruiting

NCT04241068

2020 Mar

2023 Oct

Crenezumab

(RG7412)

Monoclonal antibody

Roche/AC Immune SA

Prodromal to mild AD

IV

III

Terminated

NCT02670083

2016 Mar

2019 May

   

Prodromal to mild AD

 

III

Terminated

NCT03114657

2017 Mar

2019 Jun

   

Prodromal to mild AD

 

III

Terminated

NCT03491150

2018 Apr

2019 May

Lecanemab

(BAN2401)

Monoclonal antibody

Biogen /Eisai

Early AD

IV

III

Recruiting

NCT03887455

2019 Mar

2024 Aug

   

Preclinical AD

 

III

Recruiting

NCT04468659

2020 Jul

2027 Oct

Donanemab

(LY3002813)

Monoclonal antibody

Eli Lilly

Early symptomatic AD

IV

III

Recruiting

NCT04437511

2020 Jun

2023 Dec

   

Preclinical AD

 

III

Recruiting

NCT05026866

2021 Aug

2027 Sept

  1. AD, Alzheimer’s disease; Admin, Route of administration; SC, subcutaneous; IM, intramuscular; IV, intravenous